Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

644 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune enhancement of skin carcinogenesis by CD4+ T cells.
Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D. Daniel D, et al. J Exp Med. 2003 Apr 21;197(8):1017-28. doi: 10.1084/jem.20021047. Epub 2003 Apr 14. J Exp Med. 2003. PMID: 12695493 Free PMC article.
Vemurafenib cooperates with HPV to promote initiation of cutaneous tumors.
Holderfield M, Lorenzana E, Weisburd B, Lomovasky L, Boussemart L, Lacroix L, Tomasic G, Favre M, Vagner S, Robert C, Ghoddusi M, Daniel D, Pryer N, McCormick F, Stuart D. Holderfield M, et al. Among authors: daniel d. Cancer Res. 2014 Apr 15;74(8):2238-45. doi: 10.1158/0008-5472.CAN-13-1065-T. Epub 2014 Feb 12. Cancer Res. 2014. PMID: 24523442
Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization.
Karpov AS, Nieto-Oberhuber CM, Abrams T, Beng-Louka E, Blanco E, Chamoin S, Chene P, Dacquignies I, Daniel D, Dillon MP, Doumampouom-Metoul L, Drosos N, Fedoseev P, Furegati M, Granda B, Grotzfeld RM, Hess Clark S, Joly E, Jones D, Lacaud-Baumlin M, Lagasse-Guerro S, Lorenzana EG, Mallet W, Martyniuk P, Marzinzik AL, Mesrouze Y, Nocito S, Oei Y, Perruccio F, Piizzi G, Richard E, Rudewicz PJ, Schindler P, Velay M, Venstrom K, Wang P, Zurini M, Lafrance M. Karpov AS, et al. Among authors: daniel d. ACS Med Chem Lett. 2019 Dec 3;10(12):1674-1679. doi: 10.1021/acsmedchemlett.9b00468. eCollection 2019 Dec 12. ACS Med Chem Lett. 2019. PMID: 31857845 Free PMC article.
CSF-1R inhibition alters macrophage polarization and blocks glioma progression.
Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, Pedraza A, Zhang J, Brennan CW, Sutton JC, Holland EC, Daniel D, Joyce JA. Pyonteck SM, et al. Among authors: daniel d. Nat Med. 2013 Oct;19(10):1264-72. doi: 10.1038/nm.3337. Epub 2013 Sep 22. Nat Med. 2013. PMID: 24056773 Free PMC article.
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents.
Assi HH, Wong C, Tipton KA, Mei L, Wong K, Razo J, Chan C, Howng B, Sagert J, Krimm M, Diep L, Jang A, Nguyen MT, Lapuyade N, Singson V, Villanueva R, Paidhungat M, Liu S, Rangan V, Vasiljeva O, West JW, Richardson JH, Irving B, Daniel D, Belvin M, Kavanaugh WM. Assi HH, et al. Among authors: daniel d. Cancer Immunol Res. 2021 Dec;9(12):1451-1464. doi: 10.1158/2326-6066.CIR-21-0031. Epub 2021 Oct 11. Cancer Immunol Res. 2021. PMID: 34635485 Free PMC article.
644 results